Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration.
Jonathan H SinR H ElshabouryR M HurtadoA R LetourneauR G GandhiPublished in: Journal of clinical pharmacy and therapeutics (2017)
The presence of critical illness and renal replacement therapy can induce pharmacokinetic changes that may warrant vigilant TDM to ensure optimal therapy. To our knowledge, this is the first report to describe TDM for several antitubercular agents during CVVH in a critically patient with disseminated M. tuberculosis.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- extracorporeal membrane oxygenation
- acute kidney injury
- healthcare
- case report
- high intensity
- peritoneal dialysis
- end stage renal disease
- stem cells
- chronic kidney disease
- emergency department
- mesenchymal stem cells
- hepatitis c virus
- antiretroviral therapy
- smoking cessation